CD163 and breast cancer: Here, we report the 10-year OS, breast cancer-specific survival (BCSS) and disease-free survival (DFS) rates according to the number of M2 TAMs (CD163+) and all TAMs (CD68+) in a cohort of 278 non-metastatic breast cancer patients, every second of which was HER2+ (n = 139).